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Tuberculosis (TB) is a most common infectious disease. 
Tuberculosis (TB), caused by Mycobacterium tuberculosis, remains one 
of the biggest killers amongst the infectious diseases despite the 
availability of effective drugs and Bacillus-Calmette Guerin (BCG) 
vaccine. About one-third of world's populations are infected with M. 
tuberculosis. Every year, about 8 million of the infected people develop 
active TB, and about 2 million die of the disease [1]. In 2010, WHO 
reported that 650,000 cases of MDR-TB emerged among the world’s 12 
million prevalent cases of TB [2]. Streptomycin (STR) was the first drug 
introduced in 1944 for the treatment of TB but immediately after its 
opening many patients started showing resistance to this antibiotic 
[3,4,5]. Para-aminosalicylate (PAS) was introduced in 1946 that 
overcame the emergence of resistant strains [6]. A few years later, 
Isoniazide (INH) was developed and initial treatment with both INH and 
STR was even more effective. Many drugs are available, which are 
classified into two categories. First line therapy includes five 
medications: INH, pyrazinamide (PZA), ethambutol (EMB), rifampicin 
(RIF) and STR [7,8]. Second line therapy, which is used exceptionally in 
the cases of drug resistance, includes cycloserine, capreomycin, 
fluoroquinolones, ethionamide, PAS, thioacetazone, rifabutin, 
clofazimine and some macrolides [9]. The major setback in controlling 
TB was the emergence of multidrug resistant tuberculosis (MDR-TB). 
Currently, about 50 million people are estimated to be affected with 
MDR-TB. A few MDR strains of M. tuberculosis were found to be 
resistant to many first line agents as well as some of the second line 
drugs [10]. Even more frightening is the emergence of extensively drug 
resistant TB (XDR-TB) reported in all around the world [11]. The 
increased number of MDR strains, is closely related to the growing 
global HIV/AIDS pandemic [12]. The connection of TB and HIV 
infections is so dramatic that, nearly two-thirds of the patients 
diagnosed with TB are also HIV positive[13] and the risk of rising TB is 
between 20 and 37 times greater in individual living with HIV than 
among those who do not have HIV infection [14]. TB is the principal 
cause of death among HIV infected individual; more than a quarter of 
deaths among people living with HIV [15,16]. Furthermore, various 
studies showed the reciprocal deadly effect of these two conditions, 
since HIV infection is a major risk factor for the development of active 
TB which, in turn is a cofactor in the development of HIV infection [17]. 
The immune-suppression related to HIV infection has also caused the 
emergence of many opportunistic infections, including disseminated M. 
avium complex (MAC) infections [18-20]. People carrying latent 
infection are at a risk of reactivation and this is one of the major 
barriers in controlling tuberculosis. Therefore, there is an urgent need 
to develop novel drugs that can act against both actively growing and 
dormant mycobacteriums.  
 
2. New Potential Anti-Tubercular Agents  
The efforts for drug development are being coordinated to 
bring out new, faster-acting and affordable drugs against TB. Rational 
development of a new anti-TB drug requires the discovery of new 
means to recognize the genetics and physiology of M. tuberculosis. In 
this consideration, availability of the genome sequence of M. 
tuberculosis [21] and powerful genetic tools for manipulating 
mycobacteria have offered valuable information about the potential 
targets. Many of these target has helped in designing novel therapeutic 
agents [22]. The new potential anti-TB agents are classified on the basis 
of their chemical entities. The potential drug targets compiled in this 
review are likely to lead to new medication with pyrrole and 
pyrrolidine drug that should facilitate in controlling the spread of TB.  
 
3. Antitubercular activity of pyrrole derivatives 
Naturally occurring pyrrolnitrin (1a) and its analogs were 
tested against M. tuberculosis, and the most effective exhibited an MIC of 
3.9 mM [23]. Most of the compounds from this series were cytotoxic, 
presumably because of the nitro group. Structural optimization of 
pyrrolnitrin and other azole analogs led to the discovery of the more 
potent pyrrole, BM-212 (1b), exhibiting MIC values of 1.68 mM against 
M. tuberculosis [24]. BM-212 (1b) was also found to be effective against 
strains resistant to EMB, INH, amikacin, STR, RIF, and rifabutin, as well 
as against M. tuberculosis growing within a human monocyte cell line. 
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                         Pyrrolnitrin analog 1a                    1b R1 = 4-Cl, R2 = 4-Cl, R3 = NCH3; BM-212                          LL-3858 1h 
                                                     1c R1 = 4-F, R2 = 4-F, R3 = S 
                                                      1d R1 = 4-F, R2 = 4-F, R3= S 
                                                   1e R1, R2 = H, R3 = S 
                                                 1f R1=4-F, R2= 2-F, R3 = S 
                                                    1g R1= 4-CH3, R2 = 4-F, R3=S 
Fig. 1: Pyrrole-based antitubercular compounds 
Using BM-212 (1b) as a lead compound, systematic structural optimization led to the discovery of improved analogs, with similar or 
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Fig. 2: Activity relationship of pyrrole compound 
Based on whole cell biological activity, with aromatic groups 
at N1 and C5 and a methyl group at C2 is an essential feature (Fig. 2). The 
methylene-linked thiomorpholine or N-methylpiperazine substituents 
at C3 act as hydrogen bond acceptors to improve activity (1b-g) ([28, 
29]. Thus, a 1,2,3,5-tetrasubstituted pyrrole is the pharmacophore is 
vital for anti-TB activity (Fig. 1). The 2-methyl group is not involved in 
any pharmacophoric interaction but influences the conformation of the 
substituents at positions 1 and 3 of the pyrrole ring [28,29). Other 
pyrrole analog, LL-3858 (1h), a pyrrole derivative, also complies with 
this pharmacophore model. This compound has exhibited MIC values in 
the range of 0.05–0.1 mM, against M. tuberculosis. LL-3858 (1h) has 
been reported to sterilize the lungs and spleen of infected mice after 12 
weeks of treatment, none of which relapsed after 2 months of therapy 
termination. 
A pyrrole derivative, BM 212 [1,5-diaryl-2-methyl-3-(4-
methylpiperazin-1-yl) methyl-pyrrole], displayed potent in vitro activity 
against M. tuberculosis [24]. The MICs were 0.7-1.5 μg/ml for drug 
susceptible and resistant strains of M. tuberculosis, suggesting there is 
no cross resistance with current drugs. BM 212 also exhibited good 
activity against nontuberculous mycobacteria including M. avium 
(MIC=0.4-3.1 mg/ml). The BM 212 showed bactericidal activity against 
intracellular M. tuberculosis in a macrophage tissue culture model 
(U947 cells), with MIC of 0.5 μg/ml. A series of BM 212 derivatives were 
made in order to improve potency [25-27]. A thiomorpholine derivative 
of BM 212, in which the N-methyl piperazino methyl moiety at the C3 
position of the pyrrole ring was replaced with a thiomorpholinomethyl, 
was found to be more potent and less toxic than BM 212, with MIC of 
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4. Pyrrole and Pyrrolidine Derivatives 
Peptide deformylase (PDF) is a key enzyme, that 
deformylates the N-formylmethionine of newly synthesized 
polypeptides, a key step in protein maturation. It is also identified as a 
validating target after the identification of LBK-611 as an anti-TB agent. 
In this perception, a series of LBK-611 (2a) derivatives were prepared 
by introducing benzimidazoles and benzoxazoles moieties at 2-position 
and peptides at N-1 position. Among all, Compounds 2b and 2c have 
shown more potent IC50 of 0.010, 0.013 μM respectively against M. 
tuberculosis PDF enzyme and MIC of 0.1 μg/mL and 0.15μg/mL against 
M. tuberculosis H37Rv in comparison to LBK-611. These compounds 
also showed promising activity of MIC 0.03, 0.06μg/mL, respectively 
against M. tuberculosis MDR strain[30]. In a different approach, three 
conformationally constrained ethambutol (10) analogues having basic 
skeleton of pyrrolidine and bipyrrolidine were prepared. Among these, 
one compound 3 with semi-rigidified EMB skeleton being the part of 
pyrrolidine with cis configuration has shown modest growth inhibition 
at concentrations of over 60 μg/mL, which is 30 fold less than EMB, 
while bipyrrolidine and trans-semi-rigidified EMB skeleton was found 

























2a                              2b: X=NH 2c: X=O                                     3 
 
In search of new heterocycles with anti-TB activity, two 
different series of spiro-compounds, 1-methyl-4-(2,4-
dichlorophenyl)pyrrolo(spiro[2.3”]oxindole)spiro[3.3’]-1’-
methylpiperidin-4’-one (4) showed good activity with a MIC of 1.76 and 
0.88μM against M. tuberculosis and MDR-TB respectively [32]. While in 
an another series, compound 5 showed increased potency with MIC 
value of 0.40 μg/mL against M. tuberculosis and was 4 and 15.6 times 
more potent than EMB and PZA, respectively [33]. Pyrrolidine 
containing bis-heterocyclic libraries, bis-cyclic guanidine derivative (6) 
showed preeminent potency with a MIC of 3.9 μg/mL against M. 
tuberculosis and found to be less toxic with an IC50 of 39.48μg/mL [34]. 
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The InhA, the enoyl acyl carrier protein reductase (ENR) 
from M. tuberculosis, is a key enzyme involved in the mycobacterial fatty 
acid elongation cycle and has been validated as an effective anti-TB 
target. A series of N-substituted-2-pyrrolidine-3-carboxamides were 
prepared as potent InhA inhibitors. Among all, the racemic compound 7 
has shown inhibition of IC50 140 nM, while one of its enantiomeric 
excess molecules showed inhibition of IC50 62 nM against InhA of M. 
tuberculosis [35]. The tetramic acid (N-substituted-2,4-pyrrolidone) 
molecules with structural similarity to the antibiotic reutericyclin (8) 
were screened for their antibacterial activity. Many of them have shown 
promising potency against Gram-positive bacteria and two compounds 
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A pyrrole derivative BM 212 (9) arose the attention with its 
very good in vitro activity of MIC 0.7 μg/mL against M. tuberculosis. 
Prompted by these results, a series was developed by the variation of N-
1, C-3 and C-5 positions. Among all, compound 10 showed potent 
inhibition of MIC 0.4 μg/mL against M. tuberculosis and also the 
protection index (PI) of 20 which is more than that of BM 212 [25]. 
While compounds 11 [26] and 12 [27] showed comparable MIC of 1 
μg/mL. Surprisingly, substitution of 4-isopropyl benzene at C-5 position 
and 4-fluorobenzene at N-1 position (13) has increased the potency 
with a MIC of 0.25μg/mL, which is equal to that of isoniazid (INH) [37]. 
While by replacing 4-isopropylbenzene with 4-methylbenzene (14) [28] 
at C-5 position of compound 13 showed decreased potency of MIC 0.4 
μg/mL but lowered the toxicity.  
This made the molecule a promising lead with a protection 
index of 160, which is greater than the anti-TB drugs INH, STR. The 
introducing an ethyl group at position 2 of the pyrrole nucleus by 
keeping both N-1 and C-5 phenyl rings, the same substituents that gave 
the best activity in previous 2-methyl derivatives. Among them, 1-(4-
fluorophenyl)-2-ethyl-3-(thiomorpholin-4-yl) methyl-5-(4-
methylphenyl)-1H-pyrrole (15) proved to be particularly active, with a 
MIC 0.25 μg/mL, which is better than or comparable to those of 
reference compounds [38]. All the above compounds (10-15) were also 
active against resistant M. tuberculosis [39]. In a series of pyrrole 
derivatives obtained by the variation of N-1, C- 2, C-3 and C-4 positions, 
compound 16 was found to be most potent with a MIC of 0.5μg/ml [39]. 
By variation of simple pyrrole at N-1 position, a series of N-(4-
substituted) benzoic acid hydrazide analogs and some derived 
oxadiazole, triazole and pyrrole have been prepared. Oxadiazole-2-thiol 
















                         9                                                   10: R1=H, R2=4-F 
                                                                              11: R1=H, R2=H 
                                                                              12: R1=2-F, R2=2-F 
                                                                              13: R1=i -C3H7, R2=4-F 























The 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-
100480 and evaluated their potency as an antitubercular agents. Among 
all, compound 18 showed 90% inhibition at 5.8 μM concentrations, 
which is comparable to PNU-100480 and INH [41]. Compounds (19) 
showed equal potency of MIC 0.78 μg/mL against M. tuberculosis [42]. 
The compound 20 showed MIC of 0.39 μg/mL against M. tuberculosis 
H37Rv [43]. With the same motivation, Guillon et al[44]. synthesized a 
series of pyrrolo[l,2-a]quinoxaline-2- or -4-carboxylic acid hydrazides 
and one compound (21) showed an interesting activity at 6.25 μg/mL 
against M. tuberculosis H37Rv, with a 100 percentage inhibition [44]. 
Two series of thiophene (22) [45,46], thiophene analogues displayed 
MIC in the range 3.12-12.5 μg/mL and benzopyrrole/pyridine 
analogues displayed 6.25-25 μg/mL against M. tuberculosis H37Rv. 
Whereas, hybrid of isonicotinic hydrazone of pyrrole (23) showed best 
potency of MIC ≤0.1 μg/mL against M. tuberculosis H37Rv and also has 
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Hybridization of Spiro compound (fig 3) and pyrrolo[2,1-
b]thiazole, an unusual ring with different biological properties, 
particularly permitted the obtention of pyrrolothiazoles derivatives 
(24) that present a MIC of 0.007 μM against M. tuberculosis, being more 
potent than INH and Ciprofloxacin. A series of spiro-pyrrolothiazoles 
were evaluated for their antitubercular activity. Among all, the best 
potency was displayed by compound 25 with a MIC of 0.6 μM against 
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Fig. 3: Spiro-pyrrolothiazoles derivative with anti-TB activity. 
 
5. Discussion 
Mycobacterial infections are infectious diseases of global 
importance. Control of TB is complicated by difficulties in 
administrating the long-course chemotherapy regimens, the inability to 
eliminate latent organisms, and increasing appearance of MDR-TB. New 
drugs for the control of TB are urgently needed, including developments 
of short-term antibiotic regimens to minimize the emergence of drug 
resistance and new drugs to treat MDR-TB patients and to eradicate the 
latent bacteria. Recent years have witnessed emergence of many new 
structural classes of anti-TB agents, some of which exhibit promising 
activities against susceptible and resistant strains of M. tuberculosis. In 
particular, the newly discovered drug with superior anti-TB activity and 
encouraging results from recent studies that have generated 
considerable excitement.  
 
6. Conclusion 
In the past several years, it has been realized that controlling 
TB needs two issues to be addressed, drug resistance and persistence. A 
better understanding of the biology of tubercle bacilli, development in 
mycobacterial genetic tools, high throughput drug screening and 
structure based drug designing have increased the prospect of 
identifying novel anti-tubercle agents to combat drug resistant and 
persistent organisms. Investigation of M. tuberculosis pathogenesis has 
entered a new era and it is anticipated that the global challenge of 
tuberculosis will be surmounted in near future. In conclusion, we can 
confirm that in general pyrrole derivatives are particularly adapted to 
be used as antitubercular agents. Finally, the selectivity and the 
consistent ability to reduce the onset of cross resistance of pyrrole 
derivatives, probably due to a different mechanism of action, lead them 
to be good candidates for further development. 
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